Exscientia, the clinical stage AI drug discovery company, has appointed Dr Richard Law as Executive Vice President of Strategic Alliances. Reporting to the COO, Dr David Hallett, Richard brings further business partnering acumen to its leadership team.
This appointment comes following a year of accelerated growth for Exscientia, including announcing the first AI-designed drug to enter human clinical trials, a $70 million Series C financing round led by Novo Holdings, as well as a doubling of headcount to over 100 employees.
Richard joins Exscientia from a highly successful career at Evotec where he was Senior Vice President of Business Development for over seven years and previously Head of Computational Chemistry. Before Evotec, Richard was a senior computational chemistry researcher at the University of California, San Diego and Lawrence Livermore National Laboratories. He is also a Director on the Board of OpenEye Scientific Software. Richard holds a DPhil in Molecular Biophysics from Oxford and an MBA from the Imperial College London. At Exscientia, Richard will be responsible for driving new drug discovery collaborations as well as partnering of proprietary portfolio assets.
Commenting on the appointment, Prof Andrew Hopkins, CEO of Exscientia said, “Richard has extensive expertise in biopharma business development as well as a deep understanding of Exscientia from his research at some of the top computational chemistry laboratories in the world. Richard has the experience and relationships to substantially expand Exscientia’s collaborations using our Centaur AI-driven discovery and design platform.”
Commenting on his appointment, Richard Law said, “I am tremendously excited to join Exscientia, who have pioneered the use of AI and automation for drug discovery globally. Exscientia have demonstrated that they are the only company to use AI to create drugs with custom-optimised profiles and then move them into the clinic. Adoption of AI to more rapidly bring better medicines to patients is a necessary step change for the industry”.
Exscientia is a global leading Pharmatech company, using Artificial Intelligence (AI) to drive drug discovery and is the first AI company to have designed a novel molecule to enter the clinic. Founded in 2012, Exscientia fuses the power of AI with the experience of seasoned drug hunters. Exscientia’s innovative Centaur Chemist® platform enables breakthrough productivity gains as well as new approaches to improve drug design. Novel compounds are automatically designed and prioritized for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.
Exscientia’s Centaur Biologist® platform drives the flexible analysis and prioritisation of discovery targets across all pharmaceutically relevant disease space. Exscientia is collaborating with several leading pharmaceutical and life sciences companies as well as building its own portfolio of innovative medicines. Exscientia has its headquarters in Oxford, England with further offices in Dundee, Scotland, the USA and Japan. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI
Anitra Sprauten; Edelman UK
P: +44 (0)78 9685 9386
Stephanie Crisp; Edelman UK
P: +44 (0)75 8300 3417
Mark Swindells; Chief Commercial Officer